KalVista Pharmaceuticals (NASDAQ: KALV) and Peregrine Pharmaceuticals (NASDAQ:PPHM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Earnings and Valuation

This table compares KalVista Pharmaceuticals and Peregrine Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
KalVista Pharmaceuticals $625,000.00 158.36 -$16.21 million N/A N/A
Peregrine Pharmaceuticals $79.10 million 2.19 -$17.42 million ($0.64) -6.00

KalVista Pharmaceuticals has higher revenue, but lower earnings than Peregrine Pharmaceuticals.

Analyst Ratings

This is a summary of recent recommendations and price targets for KalVista Pharmaceuticals and Peregrine Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals 0 0 1 0 3.00
Peregrine Pharmaceuticals 0 0 1 0 3.00

KalVista Pharmaceuticals presently has a consensus price target of $18.00, suggesting a potential upside of 76.64%. Peregrine Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 160.42%. Given Peregrine Pharmaceuticals’ higher possible upside, analysts clearly believe Peregrine Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Risk and Volatility

KalVista Pharmaceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, Peregrine Pharmaceuticals has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500.

Profitability

This table compares KalVista Pharmaceuticals and Peregrine Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
KalVista Pharmaceuticals -4,191.47% -60.42% -55.11%
Peregrine Pharmaceuticals -23.15% -38.19% -16.66%

Institutional & Insider Ownership

75.7% of KalVista Pharmaceuticals shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of Peregrine Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Peregrine Pharmaceuticals beats KalVista Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.